EQS-News: Apogenix AG: Apogenix' new CD40 agonist HERA-CD40L significantly reduces tumor growth in prostate cancer model
EQS-News: Apogenix AG / Key word(s): Scientific publication Apogenix AG: Apogenix’ new CD40 agonist HERA-CD40L significantly reduces tumor growth in prostate cancer model 01.06.2023 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. Apogenix’ new CD40 agonist...
Source: boersennews.de